Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented Initiation of Phase ...

IMUNON, Inc. has announced the initiation of a Phase 3 pivotal trial, OVATION 3, for its DNA-mediated immunotherapy candidate, IMNN-001, targeting newly diagnosed advanced ovarian cancer.

LAWRENCEVILLE, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the U ...

Short interest in Imunon Inc (NASDAQ:IMNN) increased during the last reporting period, rising from 997.88K to 1.20M. This put 8.29% of the company's publicly available shares short. Short interest ...

Imunon has announced the alignment of the US Food and Drug Administration (FDA) with the Phase III OVATION 3 trial of IMNN-001 for ovarian cancer protocol. IMNN-001, the company’s lead candidate ...

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also ...

Imunon, Inc. (NASDAQ:IMNN – Get Free Report)’s share price dropped 1.9% during trading on Wednesday .The company traded as low as $0.86 and last traded at $0.86. Approximately 30,040 shares ...

Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN ...

IMUNON (IMNN) announced that an abstract highlighting new, highly encouraging, Overall Survival data from the Phase 2 OVATION 2 Study of ...

LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an ...

LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an abstract ...